Intelligence ยท Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors โ phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text โ searchable for business development and competitive intelligence.
-
68Ga-DOTA-FAPI, 177Lu-DOTA-FAPI
The First People's Hospital of Lianyungang
177Lu-DOTA-FAPI
1 trial -
68Ga-DOTA/NOTA-FAPI-04
The First People's Hospital of Lianyungang
Tumor
1 trial -
68Ga-FAPI-04
The First People's Hospital of Lianyungang
Liver Fibrosis
1 trial -
68Ga-FAPI-Biotin
The First People's Hospital of Lianyungang
Tumor
1 trial -
68Ga-JH04
The First People's Hospital of Lianyungang
Malignant Neoplasm
1 trial -
68Ga-JH12
The First People's Hospital of Lianyungang
Malignant Neoplasm
1 trial -
68Ga-MGS5
The First People's Hospital of Lianyungang
Medullary Thyroid Carcinoma
1 trial -
68Ga-NODAGA-SNA006
The First People's Hospital of Lianyungang
Solid Tumor
1 trial -
68Ga-NOTA-MAL-Cys39-exendin-4
The First People's Hospital of Lianyungang
Insulinoma
1 trial -
68Ga-PSMA-11
The First People's Hospital of Lianyungang
Prostate Cancer
1 trial -
68Ga-Pentixafor
The First People's Hospital of Lianyungang
Lymphoma
1 trial -
99mTc-QULIC-5-P1
The First People's Hospital of Lianyungang
Prostate Cancer Stage
1 trial -
A Phase I study to evaluate the safety and dosimetry of 68Ga-OncoACP3 in patients with prostate cancer
Philogen S.p.A.
Patients with prostate cancer with: -suspected metastasis who are candidates for initial definitive therapy -suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) -metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands
1 trial -
A Phase I study to evaluate the safety and dosimetry of imaging with 68Ga-OncoACP3 in prostate cancer.
Philogen S.p.A.
Patients with prostate cancer with: - suspected metastasis who are candidates for initial definitive therapy - suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) - metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands
1 trial -
A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy
Takeda
IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also known as Berger's disease)
1 trial -
A-CAR028
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia (AML)
1 trial -
AFN50 injection
The First People's Hospital of Lianyungang
Autoimmune Diseases
1 trial -
ATHENA CAR-T
The First People's Hospital of Lianyungang
Lupus Erythematosus, Systemic
1 trial -
Adebrelimab
The First People's Hospital of Lianyungang
Biliary Tract Malignancies
1 trial -
Akk Gut Bacteria Supplement
The First People's Hospital of Lianyungang
Premature Ovarian Failure (POF)
1 trial -
All-trans retinoic acid
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
Amitriptyline Hydrochloride 25Mg Tablet๏ผHunan Dongting๏ผ
The First People's Hospital of Lianyungang
Depressive Disorder
1 trial -
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Maribavir Tablets 200 mg, manufactured by Sun Pharmaceutical Industries Limited, India with LIVTENCITYยฎ (Maribavir) Coated Tablets 200 mg, manufactured by: Catalent CTS, LLC Kansas City, United States of America, packed by: Takeda Ireland Limited Bray, Ireland, imported by: Takeda Pharma Ltda. Highway SP 340 S/N, km 133.5 Jaguariรบna Administrative Building -SP CNPJ 60.397.775/
Lacuna Pharma Pty Ltd
cytomegalovirus (CMV) infection and/or disease that is refractory (with or without resistance) to one or more prior therapies in adult patients who have undergone hematopoietic stem cell transplantation (HSCT) or solid organ transplantation (SOT)
1 trial -
Anlotinib hydrochloride,Penpulimab
The First People's Hospital of Lianyungang
Colorectal Cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1โ3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync โ verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources